Cost-effectiveness of rosuvastatin for cardiovascular prevention in high-risk populations in Sweden

被引：0
|
作者：
Jonsson, L.
Ekman, M.
Karlsson, G.
Brun, J.
机构：
[1] European Hlth Econ, London, England
[2] Stockholm Hlth Econ, Stockholm, Sweden
[3] AstraZeneca, Sodertalje, Sweden
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)63646-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A346 / A346
页数：1
相关论文
共 50 条
  • [41] Anastrozole for the prevention of breast cancer in high-risk postmenopausal women: cost-effectiveness analysis in the UK and the USA
    Wei, Xiaoxia
    Cai, Jiaqin
    Lin, Huiting
    Wu, Wenhua
    Zhuang, Jie
    Sun, Hong
    BMC HEALTH SERVICES RESEARCH, 2024, 24 (01)
  • [42] The cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality - a swedish economic evaluation of the JUPITER trial
    Ohsfeldt, R. L.
    Olsson, A. G.
    Jensen, M. M.
    Gandhi, S. K.
    Paulsson, T.
    EUROPEAN HEART JOURNAL, 2010, 31 : 225 - 225
  • [43] The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden
    Zethraeus, N.
    Strom, O.
    Borgstrom, F.
    Kanis, J. A.
    Jonsson, B.
    OSTEOPOROSIS INTERNATIONAL, 2008, 19 (06) : 819 - 827
  • [44] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN SECONDARY PREVENTION OF ACS IN SWEDEN
    Begum, N.
    Van Hout, B.
    Thurston, S.
    Schoeman, O.
    Fraschke, A.
    Verheugt, F. W. A.
    VALUE IN HEALTH, 2013, 16 (07) : A524 - A524
  • [45] The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden
    N. Zethraeus
    O. Ström
    F. Borgström
    J. A. Kanis
    B. Jönsson
    Osteoporosis International, 2008, 19 : 819 - 827
  • [46] Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations
    Roland Diel
    Niklas Lampenius
    Albert Nienhaus
    PharmacoEconomics, 2015, 33 : 783 - 809
  • [47] Selecting the optimal risk threshold of diabetes risk scores to identify high-risk individuals for diabetes prevention: a cost-effectiveness analysis
    Muhlenbruch, Kristin
    Zhuo, Xiaohui
    Bardenheier, Barbara
    Shao, Hui
    Laxy, Michael
    Icks, Andrea
    Zhang, Ping
    Gregg, Edward W.
    Schulze, Matthias B.
    ACTA DIABETOLOGICA, 2020, 57 (04) : 447 - 454
  • [48] Using diabetes risk scores to select high-risk individuals for diabetes prevention in the United States: a cost-effectiveness analysis
    Muehlenbruch, K.
    Zhou, X.
    Bardenheier, B.
    Zhang, P.
    Gregg, E.
    Schulze, M. B.
    DIABETOLOGIA, 2015, 58 : S182 - S182
  • [49] Selecting the optimal risk threshold of diabetes risk scores to identify high-risk individuals for diabetes prevention: a cost-effectiveness analysis
    Kristin Mühlenbruch
    Xiaohui Zhuo
    Barbara Bardenheier
    Hui Shao
    Michael Laxy
    Andrea Icks
    Ping Zhang
    Edward W. Gregg
    Matthias B. Schulze
    Acta Diabetologica, 2020, 57 : 447 - 454
  • [50] Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations
    Diel, Roland
    Lampenius, Niklas
    Nienhaus, Albert
    PHARMACOECONOMICS, 2015, 33 (08) : 783 - 809
12345